CA1302265CCA000556617ACA556617ACA1302265CCA 1302265 CCA1302265 CCA 1302265CCA 000556617 ACA000556617 ACA 000556617ACA 556617 ACA556617 ACA 556617ACA 1302265 CCA1302265 CCA 1302265C
Authority
CA
Canada
Prior art keywords
glucuronide
nalmefene
beta
opioid
intestine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Branded Pharmaceutical Products R&D Inc
Original Assignee
Baker Cummins Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Cummins Pharmaceuticals IncfiledCriticalBaker Cummins Pharmaceuticals Inc
Priority to CA000556617ApriorityCriticalpatent/CA1302265C/fr
Application grantedgrantedCritical
Publication of CA1302265CpublicationCriticalpatent/CA1302265C/fr
N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes